Free Trial

Metsera (NASDAQ:MTSR) Stock Price Down 6.3% - Here's Why

Metsera logo with Medical background

Metsera Inc. (NASDAQ:MTSR - Get Free Report) traded down 6.3% on Monday . The company traded as low as $26.57 and last traded at $27.74. 164,075 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 921,512 shares. The stock had previously closed at $29.60.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price objective for the company. Guggenheim lifted their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Metsera presently has a consensus rating of "Buy" and an average price target of $55.00.

Get Our Latest Research Report on Metsera

Metsera Stock Up 7.7%

The stock's fifty day simple moving average is $26.34.

Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers purchased a new position in Metsera in the first quarter valued at $520,000. Strs Ohio purchased a new stake in Metsera during the 1st quarter worth about $76,000. Siren L.L.C. purchased a new stake in Metsera during the 1st quarter worth about $4,083,000. Woodline Partners LP purchased a new stake in Metsera during the 1st quarter worth about $8,172,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Metsera during the 1st quarter worth about $568,000.

Metsera Company Profile

(Get Free Report)

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Featured Stories

Should You Invest $1,000 in Metsera Right Now?

Before you consider Metsera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.

While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines